COMPANY PROFILE

Epoch Biodesign

Explore full profile

Designing and scaling the first enzymes capable of transforming plastics into low-carbon, circular chemicals

London, United KingdomFounded 2019Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Epoch Biodesign

Epoch Biodesign is a London deep-tech company that designs AI-discovered enzymes to break down and recycle plastics and textiles, including nylon 6,6, into circular chemicals at commercial scale. In March 2026 it closed a $12 million / about €10.3 million strategic funding round with lululemon, KOMPAS VC, Happiness Capital, Extantia, Leitmotif and others, bringing total capital raised to over $50 million to commercialise enzymatic nylon recycling and build a London demonstration facility (following an earlier Series A). Sources: Tech.eu 25 March 2026; EU-Startups; TechCrunch.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: London, United Kingdom
Employees: 57
Open positions: 2
Dealroom signal: 91.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Recycling, Biotechnology, Synthetic Biology, Sustainable Development Goals, Advanced Materials, Climate Tech, Circular Economy, BIA Techbio UK
Technology: Hardware, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Mar 2026	$12M	$92M	Lululemon · Extantia Capital · KOMPAS VC · Happiness Capital	↗
GRANT✓Other financing	Mar 2025	$1M	—	Government of the United Kingdom	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Epoch Biodesign website traffic

Latest recorded traffic for Epoch Biodesign is 5.1K monthly website visits, up 6.3% over the last three months. Epoch Biodesign's team grew 14% over the past year.

Latest monthly visits5.1K 3-month web change+6.3% 1-year team growth+14%

Monthly website visitsDec 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

EMEA Sales Manager - Nylon Polyamide (London Office / RemoteLondon, England, United Kingdom · Sales · Aug 11, 2026 Partnerships and Market Manager - Auto & IndustrialLondon, England, United Kingdom · Other · Feb 24, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BABactobioLondon-based biotechnology company using breakthrough technologies in synthetic biology	London, United Kingdom	Operational	51	$16M	$32M
EVEvonetixUr desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use synthetic biology on a scale not currently possible	Cambridge, United Kingdom	Operational
CBConstructive BioRealising the potential of genome rewriting to drive the next generation of bioprocesses and biopharmaceuticals	Cambridge, United Kingdom	Operational
TGTouchlight GeneticsDevelops a DNA production platform designed for the development of DNA vaccines for oncology and infectious diseases	London, United Kingdom	Operational
LALabGeniusCombining human and machine intelligence to accelerate the discovery of advanced medicines	London, United Kingdom	Operational
BRBasecamp ResearchAI-powered protein discovery and design from biodiversity	London, United Kingdom	Operational
FAFluidic AnalyticsDevelops microfluidic tools for protein analysis in research and clinical applications	Cambridge, United Kingdom	Acquired
SYSynthaceEngineering biology for health, food, energy and manufacturing.	London, United Kingdom	Operational